Mapi Pharma Ltd. is poised to present promising efficacy data for its Glatiramer Acetate Depot (GA Depot) at the upcoming American Academy of Neurology (AAN) Annual Meeting 2026. This long-acting injectable formulation targets both relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The clinical studies, including a Phase IIa trial with 30 PPMS patients and a pivotal Phase III trial involving 1,016 RMS patients, demonstrated significant EDSS (Expanded Disability Status Scale) stabilization, indicating GA Depot’s potential to slow disability progression in MS patients.

The significance of these findings lies in GA Depot’s ability to provide a long-acting treatment option, administered intramuscularly every 28 days, which could address the unmet medical needs in MS management. The data suggest that GA Depot could effectively mitigate the neurological decline associated with both RMS and PPMS, offering a new therapeutic avenue for patients who currently face limited options. With GMP approval from the Israeli Ministry of Health, Mapi plans to launch GA Depot for RMS in 2027 in Germany and other EU countries, with a global Phase III study for PPMS on the horizon.

The implications of this research extend to the broader landscape of MS treatment paradigms. If approved, GA Depot could significantly alter the standard of care for MS, shifting focus towards long-acting therapies that enhance patient compliance and improve outcomes. This development may catalyze further research into depot formulations for other chronic conditions, potentially accelerating timelines for drug development in the field of neurodegenerative diseases.

Source: globenewswire.com